Related Experiment Video
Updated: Feb 28, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.6K
Integrative Spatial Transcriptomics and Immunoinformatics for Prognostic Multi-Epitope Vaccine Construct Prediction
Maha A Aljumaa1, Maher S Alwethaynani2, Hanan Abdulrahman Sagini3
1Department of Biology, College of Science, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
Pharmaceuticals (Basel, Switzerland)
|February 27, 2026
Summary
This study designed a novel multi-epitope vaccine targeting the FKBP10 oncoprotein for synovial sarcoma (SS). The vaccine is structurally stable, immunogenic, and shows potential for effective SS immunotherapy.
Area of Science:
- Oncology
- Immunology
- Bioinformatics
Background:
- Synovial sarcoma (SS) is a rare, aggressive soft-tissue cancer with poor prognosis.
- Targeted immunotherapies are needed for effective SS treatment.
Purpose of the Study:
- To design a rational multi-epitope vaccine targeting the FKBP10 oncoprotein for SS.
- To assess the vaccine's immunogenicity and potential for engaging innate immune receptors.
Main Methods:
- Analyzed transcriptomic data to identify differentially expressed genes, focusing on FKBP10.
- Predicted B-cell and T-cell epitopes and constructed a multi-epitope vaccine with an adjuvant.
- Performed in silico analyses including physicochemical properties, structural modeling, molecular docking, and molecular dynamics simulations.
Main Results:
- FKBP10 was significantly upregulated in SS.
- Identified multiple high-affinity B-cell and T-cell epitopes.
- The designed vaccine demonstrated structural stability, strong binding to TLR4 and TLR9, and stable interactions in simulations.
Conclusions:
- The FKBP10 multi-epitope vaccine is structurally stable and immunogenic.
- The vaccine effectively engages innate immune receptors, indicating potential as an SS immunotherapeutic.
- Further research is warranted to validate its efficacy in preclinical and clinical settings.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.5K
02:07Tumor Progression
7.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K
01:31Hybridoma Technology
18.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.0K
01:30Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K